Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying consolidated statements of operations is as follows (in millions, except percentages):

	Year Ended December 31,
Net sales	2021		2020		2019
MedSurg	$	3,724	$	3,066	$	3,307
Rhythm and Neuro	3,293		2,752		3,140
Cardiovascular	4,858		3,876		4,208
Total net sales of reportable segments	11,875		9,694		10,654
All other (Specialty Pharmaceuticals)	13		219		$	81
Consolidated net sales	$	11,888	$	9,913	$	10,735

Reconciliation of depreciation by reportable segment to total [Table Text Block]

	Year Ended December 31,
Depreciation expense	2021		2020		2019
MedSurg	$	81	$	80	$	75
Rhythm and Neuro	104		96		92
Cardiovascular	167		154		138
Total depreciation expense of reportable segments	352		330		306
All other (Specialty Pharmaceuticals)	—		$	3	$	6
Consolidated depreciation expense	$	352	$	333	$	311

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

	Year Ended December 31,
Income (loss) before income taxes	2021		2020		2019
MedSurg	$	1,399	$	1,079	$	1,204
Rhythm and Neuro	607		439		666
Cardiovascular	1,448		661		1,137
Total operating income of reportable segments	3,454		2,179		3,007
All other (Specialty Pharmaceuticals)	4		143		56
Unallocated amounts:
Corporate expenses, including hedging activities	(447)		(405)		(264)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU Medical Device Regulation (MDR) implementation costs	(1,070)		(1,208)		(582)
Amortization expense	(741)		(789)		(699)
Operating income (loss)	1,199		(80)		1,518
Other income (expense), net	(123)		1		(831)
Income (loss) before income taxes	$	1,076	$	(79)	$	687

Segment operating income as percentage of net sales [Table Text Block]

Operating income of reportable segments as a percentage of net sales of reportable segments	Year Ended December 31,
	2021		2020		2019
MedSurg	37.6	%	35.2	%	36.4	%
Rhythm and Neuro	18.4	%	15.9	%	21.2	%
Cardiovascular	29.8	%	17.1	%	27.0	%

Reconciliation of Assets from Segment to Consolidated [Table Text Block]

	As of December 31,
Total assets	2021		2020
MedSurg	$	1,794	$	1,638
Rhythm and Neuro	1,981		1,827
Cardiovascular	2,821		2,461
Total assets of reportable segments	6,595		5,926
All other (Specialty Pharmaceuticals)	—		1,133
Goodwill	11,988		9,951
Other intangible assets, net	6,121		5,917
All other corporate assets	7,525		7,850
	$	32,229	$	30,777

Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]

	As of December 31,
Long-lived assets	2021		2020		2019
U.S.	$	1,190	$	1,151	$	1,148
Ireland	436		382		327
Other countries	625		551		604
Property, plant and equipment, net	2,252		2,084		2,079
Goodwill	11,988		9,951		10,176
Other intangible assets, net	6,121		5,917		7,886
Operating lease right-of-use assets in Other long-term assets	435		458		336
	$	20,795	$	18,409	$	20,477